Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...
How is one of the world’s largest pharmaceutical companies promoting sustainability and regulatory compliance throughout its ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
19h
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...
Following the report, several state legislators – including Carr, K.C. Ohaebosim, Henry Helgerson, Susan Estes, Angela ...
Loblaw divests 42 Wellwise by Shoppers stores to Verillium Health Care, focusing on pharmacy growth as the healthcare brand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback